SCHEMBL3556579

SCHEMBL3556579

Cc1ccc(S(=O)(=O)Nc2ccccc2CCCCCc2ccccc2C(=O)O)c(C)c1

nearest known ligand 0.72

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.72
HPGD P15428 2/20 0.72
HSD17B10 Q99714 2/20 0.72
SLC16A3 O15427 11/20 0.57
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MAP1LC3B Q9GZQ8 1/20 0.49
GAA P10253 1/20 0.47
GFER P55789 1/20 0.47
METAP2 P50579 1/20 0.47
HSD11B1 P28845 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3562907 0.97 ALDH1A1 (0.74) ALDH1A1HPGDHSD17B10SLC16A3MEN1
SCHEMBL3555027 0.88 SLC16A3 (0.58) ALDH1A1HPGDHSD17B10SLC16A3MEN1
SCHEMBL3564778 0.85 SLC16A3 (0.64) ALDH1A1HPGDHSD17B10SLC16A3GAA
SCHEMBL11246573 0.84 ALDH1A1 (1.00) ALDH1A1HPGDHSD17B10MEN1KMT2A
SCHEMBL3564034 0.84 SLC16A3 (0.55) ALDH1A1HPGDHSD17B10SLC16A3MEN1
SCHEMBL3557083 0.84 ALDH1A1 (0.55) ALDH1A1HPGDHSD17B10SLC16A3MEN1
SCHEMBL3552944 0.83 SLC16A3 (0.56) ALDH1A1HPGDHSD17B10SLC16A3MEN1
SCHEMBL3563725 0.83 SLC16A3 (0.65) ALDH1A1HPGDHSD17B10SLC16A3MEN1
SCHEMBL3553525 0.83 ALDH1A1 (0.60) ALDH1A1HPGDHSD17B10SLC16A3MEN1
SCHEMBL3554340 0.82 SLC16A3 (0.72) ALDH1A1HPGDHSD17B10SLC16A3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 ALDH1A1 61/4885HPGD 389/4885HSD17B10 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.